Evidence map›Paper›PMID 40740535›Full record

ArticleWorld journal of stem cells2025

First-ever stem cell therapy restores insulin independence in type 1 diabetes: A medical milestone.

Dinesh Kumar, Rajni Tanwar, Vrinda Gupta

Abstract readLetter
In one paragraph

Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Type 1 Diabetes Mellitus Pathogenesis: Mechanisms, Early Diagnostic Strategies, and Emerging Therapeutic Approaches.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dinesh KumarSchool of Pharmacy, Desh Bhagat University, Mandi Gobindgarh 147301, Punjab, India. dineshpotlia123@gmail.com.
Rajni TanwarSchool of Pharmacy, Desh Bhagat University, Mandi Gobindgarh 147301, Punjab, India.
Vrinda GuptaSchool of Pharmacy, Desh Bhagat University, Mandi Gobindgarh 147301, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell therapy has emerged as a groundbreaking treatment approach, particularly for type 1 diabetes, where the autoimmune destruction of beta cells necessitates regenerative strategies to restore insulin production. This article focuses on the recent medical milestone in which autologous stem cell therapy led to insulin independence in a type 1 diabetes patient. This article explores the role of stem cell therapy in reversing diabetes, focusing on the recent medical milestone in which stem cell therapy successfully reversed diabetes in a patient. Stem cells, particularly induced pluripotent stem cells, are used to regenerate pancreatic cells that produce insulin, thereby potentially eliminating the need for insulin injections. The study highlights both the promises and challenges of using stem cell therapy for diabetes including concerns about durability of the response, safety and long-term functionality of generated beta cells. Clinical trials and the ethical considerations of using stem cells are also discussed, along with future directions for stem cell-based diabetes therapies.

Indexed as

Autoimmune diseaseClinical trialsDiabetesInduced pluripotent stem cellsInsulin productionPancreatic regenerationRegenerative medicineStem cell therapyType 1 diabetesType 2 diabetes

Identifiers

PMID40740535
PMCPMC12305139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.